This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Centre for Molecular Oncology | |
|---|---|
| Name | Centre for Molecular Oncology |
| Established | 2000s |
| Type | research institute |
| Focus | molecular oncology, translational research |
Centre for Molecular Oncology The Centre for Molecular Oncology is a multidisciplinary research institution linking basic science with clinical practice through partnerships with hospitals, universities, and biotechnology firms. It operates at the intersection of laboratory investigation, clinical trials, and precision medicine initiatives, working alongside major cancer centers, academic departments, and regulatory bodies to accelerate therapeutic development. The centre engages clinicians, geneticists, pathologists, bioinformaticians, and industry partners to translate molecular discoveries into patient care.
The Centre for Molecular Oncology integrates laboratory platforms such as next-generation sequencing, proteomics, and single-cell analysis with clinical trial units, hospital oncology wards, and pathology services, collaborating with institutions like Dana–Farber Cancer Institute, MD Anderson Cancer Center, Mayo Clinic, Johns Hopkins Hospital, Royal Marsden Hospital, Gustave Roussy, Memorial Sloan Kettering Cancer Center, Institut Curie, Peter MacCallum Cancer Centre, Karolinska Institutet, University College London Hospitals NHS Foundation Trust, Massachusetts General Hospital, University of Texas Southwestern Medical Center, Cleveland Clinic, Vall d'Hebron University Hospital, King's College London, University of Oxford, University of Cambridge, Stanford Health Care, Yale Cancer Center, Mount Sinai Health System, Fred Hutchinson Cancer Center, European Molecular Biology Laboratory, Wellcome Trust Sanger Institute, Broad Institute, European Organisation for Research and Treatment of Cancer, National Cancer Institute, National Institutes of Health, Cancer Research UK, Ludwig Institute for Cancer Research, European Society for Medical Oncology, American Association for Cancer Research, American Society of Clinical Oncology, International Agency for Research on Cancer, World Health Organization.
Founded amid the genomic revolution, the centre was shaped by milestones such as the completion of the Human Genome Project, the rise of next-generation sequencing, and landmark approvals like trastuzumab and imatinib. Early collaborations involved laboratory groups at Cold Spring Harbor Laboratory, Sanger Institute, and clinical departments at University of California, San Francisco, Imperial College London, and University of Toronto. Influential conferences at AACR Annual Meeting, ESMO Congress, and ASCO Annual Meeting helped define translational priorities, while policy dialogues with European Commission, U.S. Food and Drug Administration, and National Institute for Health and Care Excellence influenced clinical implementation. Key figures from institutions such as Memorial Sloan Kettering Cancer Center, Dana–Farber Cancer Institute, and Broad Institute contributed to program design.
The centre runs thematic programs in cancer genomics, immuno-oncology, targeted therapy, tumor microenvironment, liquid biopsy, and epigenetics, partnering with units at Broad Institute, Wellcome Trust Sanger Institute, European Molecular Biology Laboratory, Cold Spring Harbor Laboratory, Institut Curie, Gustave Roussy, MD Anderson Cancer Center, Dana–Farber Cancer Institute, Fred Hutchinson Cancer Center, Stanford University School of Medicine, Harvard Medical School, Yale School of Medicine, University of Cambridge, University of Oxford, Karolinska Institutet, Max Planck Society, National Cancer Institute, Cancer Research UK, Ludwig Institute for Cancer Research, European Organisation for Research and Treatment of Cancer, American Association for Cancer Research, American Society of Clinical Oncology, European Society for Medical Oncology. Projects include biomarker discovery for therapies like pembrolizumab, nivolumab, olaparib, and studies building on discoveries from The Cancer Genome Atlas and International Cancer Genome Consortium. Methodological collaborations involve groups at Sanger Institute, Broad Institute, Wellcome Sanger Institute, and technology partners such as Illumina, Thermo Fisher Scientific, and Oxford Nanopore Technologies.
Clinical translation is conducted through trial networks linked to hospitals and cooperative groups including EORTC, NCT (Germany), NIHR Clinical Research Network, SWOG, Alliance for Clinical Trials in Oncology, and UK National Cancer Research Institute. The centre supports early-phase trials, molecular tumor boards, and companion diagnostic development together with pathology services at Royal Marsden Hospital, Gustave Roussy, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and regulatory engagement with U.S. Food and Drug Administration, European Medicines Agency, and Medicines and Healthcare products Regulatory Agency. Precision oncology clinics integrate genomic profiling platforms from Broad Institute, Foundation Medicine, Guardant Health, and imaging collaborations with Royal Marsden and Mount Sinai radiology departments.
Training programs include postgraduate fellowships, clinician scientist tracks, and short courses co-delivered with universities and societies such as Harvard Medical School, Stanford University School of Medicine, University of Cambridge, University of Oxford, Karolinska Institutet, Cold Spring Harbor Laboratory, Wellcome Trust, European Molecular Biology Laboratory, Broad Institute, AACR, ASCO, and ESMO. The centre hosts workshops on bioinformatics, clinical trial design, and regulatory science with speakers drawn from National Cancer Institute, Cancer Research UK, Ludwig Institute for Cancer Research, Wellcome Trust Sanger Institute, and industry partners like Roche, AstraZeneca, Novartis, Pfizer, and Bristol Myers Squibb.
Strategic alliances include academic consortia, research hospitals, biotechnology firms, and philanthropic organizations such as Bill & Melinda Gates Foundation, Wellcome Trust, Ludwig Institute for Cancer Research, European Commission, NIH, Cancer Research UK, and industry collaborations with Roche, Novartis, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies, Foundation Medicine, Guardant Health. Multicenter research programs coordinate with networks such as The Cancer Genome Atlas, International Cancer Genome Consortium, European Organisation for Research and Treatment of Cancer, NCI-MATCH, and regional hubs like European Molecular Biology Laboratory and Wellcome Trust Sanger Institute.
Funding streams combine competitive grants from agencies like National Institutes of Health, National Cancer Institute, Cancer Research UK, European Research Council, Wellcome Trust, and philanthropic support from Bill & Melinda Gates Foundation and private donors. Governance structures align with oversight frameworks used by institutions such as Johns Hopkins University, Harvard University, University of Oxford, University of Cambridge, Imperial College London, and compliance guidance from U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and ethics review boards modeled after those at Massachusetts General Hospital and Mayo Clinic.
Category:Cancer research institutes